NCT02829957View on ClinicalTrials.gov

RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

19

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 13, 2020

Study Completion Date

February 13, 2020

Conditions
Venous ThromboembolismMenstruation
Interventions
DRUG

Apixaban

10mg BID for 7 days, then 5mg BID for three months

DRUG

Rivaroxaban

15mg BID for 7 days, then 20mg daily for three months

Trial Locations (2)

46202

Eskenazi Health System, Indianapolis

Indiana University Health Methodist Hospital, Indianapolis

All Listed Sponsors
lead

Indiana University

OTHER

NCT02829957 - RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding | Biotech Hunter | Biotech Hunter